



A journey through clinical trials



SCIENTIFIC RESEARCH AND INTERNATIONAL COOPERATION DIVISION

ALL RIGHTS RESERVED. No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, or stored in a database or retrieval system, without the prior knowledge and permission of the authors.

Małgorzata Piotrowicz Screenplay, text and editing Copyright (C) Małgorzata Piotrowicz Beata Dyszkiewicz-Dziadak Illustrations, typesetting and graphic design, cover design

Copyright 🛈 Beata Dyszkiewicz-Dziadak

Project coordination Mariusz Piotrowicz Scientific and medical consultation Aleksander Wiśniewski, RN, MSc, PhD Translation Alicja Gągała Printing and binding LUNO Łukasz Nowak, Józefów

printed version ISBN 978-83-965384-1-3 PDF version, colour ISBN 978-83-965384-2-0 PDF version, black and white ISBN 978-83-965384-3-7

Electronic version available at: https://nauka.czd.pl/en/clinical-trials/

Warsaw 2022









This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777389. The Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. **Publication financed by the project conect4children - COllaborative Network for European Clinical Trials for Children**

















DIFFICULT WORDS AND THINGS THE WOLF DID NOT UNDERSTAND

- **ACTIVE COMPARATOR DRUG** a currently known drug used in a given disease. It may be given to control subjects if the purpose of the study is to determine whether the investigational substance may be a better drug than those currently available.
- **INVESTIGATOR** a scientist, usually a doctor, responsible for the proper conduct of a clinical trial. He or she is concerned about the safety of each participant in the study.
- **CLINICAL TRIAL** a scientific study that we carry out to find out whether an investigational product will be effective, safe and a better medicine than those we already know and use.
- **DOUBLE-BLIND STUDY** a situation in which neither the investigators nor the participants know who is receiving the investigational medicine.
- **INFORMED CONSENT FORM** a document in which the participant (or the person responsible for them), agrees to take part in a study. Informed consent means that he or she has been informed in advance about what the experiment will provide and the risks involved.
- **CONTROL GROUP** a group of patients who receive a placebo or other best medicine for the disease in question.
- **BIOETHICS COMMITTEE** a group of experts, i.e. clever people who check whether the idea for a clinical trial is legal and whether conducting it is necessary and will contribute to improving the quality of treatment.
- **INCLUSION/EXCLUSION CRITERIA** important information to determine whether a person can participate in a clinical trial (e.g. is he or she of the right age, does he or she have certain medical symptoms, does he or she agree to participate).
- **TRIAL SITE** the place where the clinical trial is conducted.

PLACEBO – a substance that neither harms nor helps. can be given to control subjects if a cure for the disease is not yet known.

PROCEDURE – a list of tasks to be performed with each participant during a clinical trial.

- **CLINICAL TRIAL PROTOCOL** a very important and detailed document that describes step by step how the trial will be conducted.
- **RANDOMISATION** dividing patients into two groups (study and control) by random allocation.
- **SIDE EFFECTS** unwanted effects of a drug, e.g. abdominal pain, fever, which may occur while taking it.

STUDY PARTICIPANT - a person taking part in a study.



I am delighted that this comic book was created. I believe that this form will allow children to understand the importance of clinical trials.

Marek Migdal, MD, PhD

General Director of Children's Memorial Health Institute

I come from a generation raised on comics and believe that they can explain even difficult issues to children well. We want children, including our patients, to have a good understanding of clinical research. It is the advances in medical science that give many of them an opportunity for life and for health that they would not have had decades ago. This is what the wolf learns in the nightly talks - he will from now on be our hero and partner in our daily work with young patients.

Professor Piotr Socha, MD, PhD

Deputy Director of Science, Children's Memorial Health Institute

The comic book on the key issues of clinical trials is an excellent tool to help inform and educate broad populations of children and adolescents about the difficult subject of clinical trials. Any young person who has a disease may face the possibility of taking part in a clinical trial, and it is vital that they understand what this means for them, make an informed decision and feel that they are an important part of the clinical trial. *Antoni Jedrzejewski, PhD*

President of the GCP.pl Association

In paediatrics, very many medicines are used outside the scope of their official registration indications. This is primarily due to the relatively small number of clinical trials conducted with paediatric patients. In future, more studies will mean more available, well-studied and safe therapies for the youngest patients, so it is worth raising awareness of clinical trials. The comic book "A journey through clinical trials" explains in an accessible and attractive way why and how clinical trials are conducted. It can become an invaluable aid in discussions with children and young people who are being offered the chance to take part in trials, and can also be used to help explain to children and young people how we know which drugs are effective and safe for them.

Professor Katarzyna Kotulska- Jóźwiak, MD, PhD

Head of the Department of Neurology and Epileptology, Children's Memorial Health Institute





printed version PDF version, colour PDF version, black and white ISBN 978-83-965384-1-3 ISBN 978-83-965384-2-0 ISBN 978-83-965384-3-7